This paper appears in the following:
- Donanemab Confirms: Clearing Plaques Slows Decline—By a Bit
- On Donanemab, Plaques Plummet. Off Donanemab, They Stay Away
- AL001 Boosts Progranulin. Does it Slow Frontotemporal Dementia?
- Lecanemab Follows Aduhelm’s Path to Accelerated Approval
- Donanemab Phase 3 Puts Plasma p-Tau, Remote Assessments to the Test